Fungal chitosan active ingredient for weight management in companion animals

Overview

Mykito Sciences offers a fungal-derived chitosan active ingredient designed to support healthy weight management in companion animals. Delivered as a powder that can be incorporated into existing dog and cat diets, treats, and supplements, this ingredient addresses the growing need for science-backed weight management solutions in pet nutrition. It combines two complementary mechanisms: binding dietary fats in the gastrointestinal tract to reduce fat absorption, and modulating appetite and satiety pathways to reduce voluntary food intake. Unlike traditional crustacean-derived chitosan, the fungal source provides a consistent, scalable, non-animal alternative with a lower environmental footprint through upcycled fungal biomass, and it holds established FDA GRAS precedents that support a clear regulatory path.

Technical specifications

Mechanism of action:

• Fat binding: interacts with dietary lipids and bile-associated components in the gut, reducing fat absorption.
• Appetite modulation: increases circulating leptin and alters appetite-regulating gene expression, leading to reduced food intake.
• Lean mass preservation: pig studies report reduced fat deposition with increased lean-mass percentage; human trials show modest reductions in body weight and body fat.

Product features:

• Produced by proprietary fermentation, yielding high-purity, non-animal chitosan free from common contaminants such as beta-glucans and heavy metals.
• Manufactured under a GMP-compliant quality system in ISO 22000-certified facilities, ensuring traceability and batch-to-batch consistency.
• Formulation flexibility: suitable for dry food, wet food, and treat applications, with inclusion rates pending sensory and palatability testing.

Validation plan:

• Stage 1: joint evaluation of fat-binding capacity, thermal stability, and palatability in target product formats.
• Stage 2: pilot feeding trial in dogs and/or cats measuring body weight, body condition score, and voluntary intake, with metabolic biomarkers such as leptin as secondary endpoints.
• Stage 3: regulatory alignment for GRAS/EU feed-material status at the final inclusion rate.

Technology readiness level

The ingredient is currently at an early development stage for pet applications (TRL 3–4). The weight-management mechanisms are supported by published human clinical studies and controlled pig trials, and the manufacturing process is commercially proven for other markets. However, species-specific efficacy and safety in dogs and cats have not yet been established. The proposed validation pathway moves through technical characterization, a pilot feeding trial, and regulatory alignment to bring the ingredient to market-ready status.